Sage Journals: Discover world-class research

Abstract

Background

The risks and benefits of sodium-glucose co-transporter 2 (SGLT2) inhibitors on cardiovascular outcomes have not been well established. We pooled evidence from all available clinical trials to assess the cardiovascular effects of this drug.

Design

A systematic review and meta-analysis of randomised controlled trials.

Methods

We queried electronic databases (MEDLINE, Scopus, CENTRAL and clinicaltrials.gov) from their inception to July 2017 for published and unpublished placebo controlled trials of SGLT2 inhibitors. Only studies with a follow-up period of at least 24 weeks and reporting at least one cardiovascular outcome were included. Results from trials were presented as odds ratios (ORs) with 95% confidence intervals (CIs) and were pooled using a random-effects model.

Results

Thirty-five eligible studies (canagliflozin, nine; empagliflozin, eight; dapagliflozin, 18), consisting of 34,987 patients with type 2 diabetes mellitus were included. Pooled results show that SGLT2 inhibitors, when compared to placebo, significantly reduce all-cause mortality (OR 0.79, 95% CI 0.70–0.89; P < 0.001), major adverse cardiac events (OR 0.8, 95% CI 0.76–0.92; P < 0.001), non-fatal myocardial infarction (OR 0.85, 95% CI 0.73–0.98; P = 0.03) and heart failure/hospitalisation for heart failure (OR 0.67, 95% CI 0.59–0.76; P < 0.001) in patients with type 2 diabetes mellitus. No significant difference was noted in the occurrence of stroke (OR 1.02, 95% CI 0.85–1.21; P = 0.87), atrial fibrillation (OR 0.61, 95% CI 0.31–1.19; P = 0.15) or unstable angina (OR 0.95, 95% CI 0.73–1.25; P = 0.73). In addition, there was no heterogeneity between different drugs in the SGLT2 inhibitor class for all of the clinical outcomes studied (I²= 0).

Conclusions

SGLT2 inhibitors significantly reduce the incidence of mortality, major adverse cardiac events, non-fatal myocardial infarction and heart failure in patients with type 2 diabetes mellitus. Subtypes of SGLT2 inhibitors appear to have similar cardiovascular effects.

Keywords

Sodium-glucose co-transporter SGLT2 cardiovascular outcomes meta-analysis diabetes mellitus

Get full access to this article

View all access options for this article.

References

Khalil

Roussel

Mohammedi

et al.

Cause-specific mortality in diabetes: recent changes in trend mortality. Eur J Prev Cardiol 2011; 19: 374–381.

Tang

Fang

Wang

et al.

Meta-analysis of effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes and all-cause mortality among patients with type 2 diabetes mellitus. Am J Cardiol 2016; 118: 1774–1780.

Zinman

Wanner

Lachin

et al.

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.

Neal

Perkovic

Mahaffey

et al.

Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644–657.

Arnold

Inzucchi

Tang

et al.

Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: an NCDR® Research to Practice project. Eur J Prev Cardiol 2017; 15: 1637–1645.

Saad

Mahmoud

Elgendy

et al.

Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: a meta-analysis of placebo-controlled randomized trials. Int J Cardiol 2017; 228: 352–358.

Foote

Blomster

et al.

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016; 4: 411–419.

Hutton

Salanti

Caldwell

et al.

The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015; 162: 777–784.

Higgins

Altman

Gøtzsche

et al.

The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928–d5928.

10.

Turnbull

Abraira

Anderson

et al.

Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288–2298.

11.

Hayward

Reaven

Wiitala

et al.

Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 372: 2197–2206.

12.

Holman

Paul

Bethel

et al.

10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–1589.

13.

Gerstein

Miller

Genuth

et al.

ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364: 818–828.

14.

Fitchett

Zinman

Wanner

et al.

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 2016; 37: 1526–1534.

15.

Norhammar

Mellbin

Cosentino

. Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor. Eur J Prev Cardiol 2017; 24: 52–60.

16.

Chilton

Tikkanen

Cannon

et al.

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 2015; 17: 1180–1193.

17.

Sattar

McLaren

Kristensen

et al.

SGLT2 inhibition and cardiovascular events: why did EMPA-REG OUTCOMES surprise and what were the likely mechanisms?

Diabetologia 2016; 59: 1333–1339.

18.

ClinicalTrials.gov. Safety and effectiveness of SGLT-2 inhibitors in patients with heart failure and diabetes. https://clinicaltrials.gov/ct2/show/NCT02397421 (2015, accessed 10 September 2017).

19.

ClinicalTrials.gov. Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events. https://clinicaltrials.gov/ct2/show/NCT01730534 (2012, accessed 10 September 2017).

20.

Liu

Zhang

Chen

et al.

Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years. J Diabetes Complications 2015; 29: 1295–1303.

21.

Yang

et al.

Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis. Eur J Clin Pharmacol 2015; 71: 1325–1332.

22.

Sun

Zhou

Chen

et al.

The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials. BMJ Open 2014; 4: e004619–e004619.

23.

Packer

Anker

Butler

et al.

Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol 2017; 2: 1025–1029.

24.

Pessoa

Campos

Carraro-Lacroix

et al.

Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule. J Am Soc Nephrol 2014; 25: 2028–2039.

25.

Inoue

dos Santos

Pessoa

et al.

Increased NHE3 abundance and transport activity in renal proximal tubule of rats with heart failure. Am J Physiol Regul Integr Comp Physiol 2012; 302: R166–R174.

26.

Joubert

Jagu

Montaigne

et al.

The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model. Diabetes 2017; 66: 1030–1040.

27.

Lee

Chang

Lin

. Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiacfibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med 2017; 104: 298–310.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.39 MB

Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis

Abstract

Background

Design

Methods

Results

Conclusions

Keywords

Get full access to this article

References

Supplementary Material